Blueprint Shows Promise in GIST and HCC

Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...

February 16, 2017

A completely novel approach to targeting hematologic malignancies

A look at the deeper side of research - how the spliceosome and RNA splicing may be useful in cancer research.

February 15, 2017

Novel Targets in Multiple Myeloma

Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?

February 8, 2017

Targeting the tumour environment in Lymphomas

What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.

February 6, 2017

The future of CAR T cells in pediatric ALL

Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL

January 9, 2017

Promising new agents to watch out for in Chronic Lymphocytic Leukemia

A look at some promising agents in new product development emerging in early CLL trials

January 6, 2017

The Changing CLL Landscape Part 1

How are recently approved novel therapies impacting the CLL landscape and where are we going next?

January 5, 2017

Does Polatuzumab Vedotin have Potential in Lymphomas?

A look at the latest data for a CD79b targeted ADC in lymphomas

January 4, 2017

Seattle Genetics vadastuximab talirine and liver toxicities in AML

An in-depth look at the sudden and unexpected announcement underlying the clinical hold for Seattle Genetics anti-CD33 ADC Vadastuximab Talirine in AML.

December 28, 2016

How the Leukemia Lymphoma Society plans to Beat AML

Tackling heterogeneity in older people with AML using novel targeted therapies.

December 21, 2016

LeonardList showcases 10 Lymphoma Abstracts at ASH16

#LeonardList showcases 10 Lymphoma Abstracts at ASH16

December 19, 2016

Post ASH16 Reader Q+A on CAR T cell therapies

We answer more questions on CAR T cell therapies and ADCs in acute leukemias from ASH

December 16, 2016

ASH16 Update on BCMA CAR T cell therapies

A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma

December 14, 2016
Pedicab at ASH16 in San Diego

Highlights of ASH 2016 Part 2

We answer several critical questions that readers have sent in based on the CAR T cell data at ASH this week.

December 8, 2016
Downtown San Diego during ASH 2016

7 Things I Learned at #ASH16

Highlights (Part 1) from 2016 ASH Annual Meeting in San Diego - 7 initial impressions

December 6, 2016
ASH15 Late Breaker Session

ASH16 Super Friday Preview

If you have plans to be in San Diego for #ASH16 what should you attend on Friday?

November 28, 2016

Juno plays Russian Roulette with JCAR015

A most unfortunate follow-up to the ongoing safety issues with Juno's JCAR015 and neurotoxicity in the run-up to #ASH16

November 23, 2016

ASH16 Preview on Acute Myeloid Leukemia AML

An in-depth review of what to expect from AML new product development in San Diego

November 11, 2016

ASH16 Preview of CAR T Cell Therapies

What To Watch Out For in CAR T Cell Therapies at ASH in San Diego in December 2016

November 7, 2016

ASH16 Abstracts are out! So What’s Hot at ASH16? My Initial Impressions

Initial impressions of abstracts for ASH16 in San Diego

November 3, 2016